XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.1
REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenue recognition $ 64,477 $ 54,521
Sales of generic pharmaceutical products    
Revenue recognition 49,107 32,988
Sales of established brand pharmaceutical products    
Revenue recognition 8,452 7,517
Sales of rare disease pharmaceutical products    
Revenue recognition 1,292  
Sales of contract manufactured products    
Revenue recognition 2,904 2,573
Royalties from licensing agreements    
Revenue recognition 1,903 11,210
Product development services    
Revenue recognition 566 158
Other    
Revenue recognition $ 253 $ 75